Skip to main content
SpringerLink
Log in

Telithromycin

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Telithromycin is the first member of a new family of the macrolide-lincosamide-streptogramin-B (MLSB) class of antimicrobials, the ketolides. It has a good spectrum of activity against respiratory pathogens, including penicillin- and erythromycin-resistant pneumococci, as well as intracellular and atypical bacteria. Furthermore, it has a low potential to select for resistance or induce cross-resistance among other MLSB antimicrobials.

  • ▴ At the recommended dosage of 800mg orally once daily, telithromycin reaches maximal plasma concentrations of about 2 mg/L. It penetrates rapidly into bronchopulmonary, tonsillar, sinus and middle ear tissues and/or fluids and achieves high concentrations at sites of infection. It also concentrates within polymorphonuclear neutrophils.

  • ▴ In clinical trials in patients with community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) or pharyngitis/tonsillitis caused by group A β-haemolytic streptococci, telithromycin 800mg once daily achieved clinical cure rates of 86 to 95%. In acute maxillary sinusitis (AMS), cure rates were 73 to 91%.

  • ▴ A 7- to 10-day regimen of telithromycin was as effective as a 10-day course of amoxicillin 1000mg 3 times daily, clarithromycin 500mg twice daily or a 7- to 10-day course of trovafloxacin 200mg once daily for treating CAP. A 5-day regimen of telithromycin was as effective as a 10-day regimen of cefuroxime axetil 500mg twice daily or amoxicillin/clavulanic acid 500/125mg 3 times daily in AECB.

  • ▴ A 5-day regimen of telithromycin was as effective as a 10-day regimen of clarithromycin 250mg twice daily or phenoxymethylpenicillin 500mg 3 times daily in pharyngitis/tonsillitis, or a 10-day regimen of amoxicillin/clavulanic acid 500/125mg 3 times daily in patients with AMS.

  • ▴ Telithromycin was well tolerated across all patient populations. Adverse events associated with telithromycin were generally mild to moderate in intensity and seldom led to treatment discontinuation. The most frequent adverse events were diarrhoea (13.3%) and nausea (8.1%). Other adverse events included dizziness and vomiting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bryskier A. New research in macrolides and ketolides since 1997. Expert Opin Invest Drug 1999; 8(8): 1171–94

    Article  CAS  Google Scholar 

  2. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol 1998; 37(6): 418–25

    Article  PubMed  CAS  Google Scholar 

  3. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000; 36(1): 183–93

    Article  PubMed  CAS  Google Scholar 

  4. Leroy B, Rangaraju M. High in vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens [abstract no. 2224]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  5. Davies TA, Kelly LM, Jacobs MR, et al. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E-test, and disk diffusion methodologies. J Clin Microbiol 2000; 38: 1444–8

    PubMed  CAS  Google Scholar 

  6. Barry AL, Fuchs PC, Brown SD. Tentative interpretive criteria for HMR 3647 disk diffusion susceptibility tests [abstract no. 1.01]. 4th International Congress on the Macrolides, Azalides, Streptogramins and Ketolides; 1998 Jan 21–23; Barcelona

  7. Drusano GL, Preston SL, Decosta P, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP) [abstract no. 1388]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 28

  8. Pankuch GA, Visalli MA, Jacobs MR, et al. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998 Mar; 42: 624–30

    PubMed  CAS  Google Scholar 

  9. Morosini MI, Canton R, Loza E, et al. Distribution of erythromycin A resistance determinants in Spanish Streptococcus pneumoniae isolates and comparative activity of telithromycin (HMR 3647) [abstract no. 2157]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  10. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristindalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998 Apr; 42: 945–6

    PubMed  CAS  Google Scholar 

  11. Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998 Aug; 42: 2138–40

    PubMed  CAS  Google Scholar 

  12. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Monixella catarrhalis. Diagn Microbiol Infect Dis 1999 Sep; 35: 37–44

    Article  PubMed  CAS  Google Scholar 

  13. Agouridas C, Bonnefoy A, Chantot JF. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract no. 1.11]. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides; 1998 Jan 21–23; Barcelona

  14. Felmingham D, Harding I. Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irrespective of penicillin, macrolide or fluoroquinolone resistance [abstract no. P1253]. 11th European Congress on Clinical Microbiology and Infectious Diseases; 2001 Apr 1–4; Istanbul. Clin Microbiol Infect 2001; 7 Suppl. 1:263

    Google Scholar 

  15. Mittermayer H, Jebelean C, Bocksrucker A, et al. Activity of telithromycin (HMR 3647) against erythromycin-susceptible and -resistant isolates of Streptococcus pneumoniae and Streptococcus pyogenes from Austria [abstract no. 2145]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  16. Appelbaum PC, Kelly LM, Hryniewicz W, et al. Activity of telithromycin (HMR 3647) against 599 S. pyogenes from ten central and eastern European countries [abstract no. 2153]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  17. Morrissey I, Trezise E, Tsa N, et al. The comparative in vitro activity of telithromycin (HMR 3647) against isolates of Streptococcus pyogenes (Lancefield Serogroup A) circulating in Great Britain, Northern Ireland and the Republic of Ireland during late 1999 [abstract no. 2149]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  18. Nagai K, Davies TA, Appelbaum PC, et al. Mechanism of macrolide resistance in Streptococcus pneumoniae and Streptococcus pyogenes from central and eastern European countries [abstract no. 0138]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  19. Boswell FJ, Andrews JM, Ashby JP, et al. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother 1998 Dec; 42: 703–9

    Article  PubMed  CAS  Google Scholar 

  20. Jones RN, Biedenbach DJ. Antimicrobial activity of RU-66647, a new ketolide. Diagn Microbiol Infect Dis 1997 Jan–Feb; 27: 7–12

    Article  PubMed  CAS  Google Scholar 

  21. Felmingham D, Robbins MJ, Leakey A, et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates [abstract no. F-116 and poster]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 166

  22. Schmitz F-J, Sadurski R, Kray A, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium. isolates from 24 European university hospitals. J Antimicrob Chemother 2000; 45(6): 891–4

    Article  PubMed  CAS  Google Scholar 

  23. Kitzis MD, Goldstein FW, Bismuth R, et al. Comparative in vitro activity of HMR 3647, a new ketolide antibiotic, against S. aureus (SA) and coagulase negative staphylococci (CNS) [abstract no. F-111 and poster]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 165

  24. Wootton M, Bowker KE, Janowska A, et al. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci. J Antimicrob Chemother 1999 Oct; 44: 445–53

    Article  PubMed  CAS  Google Scholar 

  25. Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998 Jun; 31: 349–53

    Article  PubMed  CAS  Google Scholar 

  26. Bebear CM, Renaudin H, Bryskier A, et al. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000; 44: 1980–2

    Article  PubMed  CAS  Google Scholar 

  27. Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000 May; 44: 1381–2

    Article  PubMed  CAS  Google Scholar 

  28. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998 Jun; 42: 1515–6

    PubMed  CAS  Google Scholar 

  29. Schülin T, Wennersten CB, Ferraro MJ, et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998 Jun; 42: 1520–3

    PubMed  Google Scholar 

  30. Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999 Jan; 43: 90–5

    PubMed  CAS  Google Scholar 

  31. Rastogi N, Goh KS, Berchel M, et al. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7. 4. Antimicrob Agents Chemother 2000; 44(10): 2848–52

    Article  CAS  Google Scholar 

  32. Fuchs PC, Barry AL, Brown SD. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin. J Clin Microbiol 2001; 39(1): 43–6

    Article  PubMed  CAS  Google Scholar 

  33. Soussy CJ, Goldstein F, Bryskier A, et al. Telithromycin (TEL): assessment of susceptibility testing [abstract no. 321]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20

  34. Zinner SH, Gilbert D, Simmons K, et al. HMR 3647 activity against penicillin- and erythromycin-sensitive and -resistant Streptococcus pneumoniae in a two-compartment in vitro dynamic model that mimics human pharmacokinetics [abstract no. M 302]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 51

    Google Scholar 

  35. Odenholt I, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001; 45(1): 23–9

    Article  PubMed  CAS  Google Scholar 

  36. Pankuch GA, Hoellman DB, Lin G, et al. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother 1998 Nov; 42: 3032–4

    PubMed  CAS  Google Scholar 

  37. Felmingham D, Clark S, Robbins MJ, et al. In vitro bactericidal activity of HMR 3647 against respiratory tract pathogens [abstract E-133]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 207

  38. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1998 Feb; 41: 149–53

    Article  PubMed  CAS  Google Scholar 

  39. Gustafsson I, Hjelm E, Cars O. In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000; 44: 1846–9

    Article  PubMed  CAS  Google Scholar 

  40. Baltch AL, Smith RP, Ritz WJ, et al. Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila. J Antimicrob Chemother 2000; 46: 51–5

    Article  PubMed  CAS  Google Scholar 

  41. Munckhof WJ, Borlace G, Turnidge J. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob Agents Chemother 2000; 44: 1749–53

    Article  PubMed  CAS  Google Scholar 

  42. Piper KE, Rouse MS, Steckelberg JM, et al. Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob Agents Chemother 1999 Mar; 43: 708–10

    PubMed  CAS  Google Scholar 

  43. Rajagopalan-Levasseur P, Vallee E, Agouridas C, et al. HMR 3647: activity against erythromycin-resistant pneumococci and Haemophilus influenzae in murine pneumonia models [abstract no. F-260]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 190

  44. Piroth L, Desbiolles N, Mateo-Ponce V, et al. HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 33–42

    Article  PubMed  CAS  Google Scholar 

  45. Agouridas C, Bonnefoy A, Chantot JF. In vivo antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract F-257]. 4th International Congress on the Macrolides, Azalides, Streptogramins and Ketolides; 1998 Jan 21–23; Barcelona, 189

  46. Rajagopalan-Levasseur P, Vallee E, Bonnefoy A, et al. HMR 3647: activity against Legionella pneumophila serogroup 1 (Lp1) in monocyte-derived macrophages and in experimental guinea pig infection models [abstract no. B-47]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 58

  47. Vesga O, Bonnat C, Craig WA. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [abstract no. F-255]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 189

  48. Craig WA, Andes DR. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae [abstract no. 2141]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 32

  49. Chu DTW. Recent developments in macrolides and ketolides. Current Opinion in Microbiology 1999; 2(5): 467–74

    Article  PubMed  CAS  Google Scholar 

  50. Bonnefoy A, Girard AM, Agouridas C, et al. Ketolides lack inducibility properties of MLS. resistance phenotype. J Antimicrob Chemother 1997; 40: 85–90

    Article  PubMed  CAS  Google Scholar 

  51. Reinert RR, Bryskier A, Lütticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother 1998 Jun; 42: 1509–11

    PubMed  CAS  Google Scholar 

  52. Hamilton-Miller JM, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J Antimicrob Chemother 1998 Jun; 41: 649–53

    Article  PubMed  CAS  Google Scholar 

  53. Davies TA, Dewasse BE, Jacobs MR, et al. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000 Feb; 44: 414–7

    Article  PubMed  CAS  Google Scholar 

  54. Edlund C, Alván G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000; 46: 741–9

    Article  PubMed  CAS  Google Scholar 

  55. Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001; 45(1): 170–5

    Article  PubMed  CAS  Google Scholar 

  56. Lenfant B, Sultan E, Wable C, et al. Pharmacokinetics of 800mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers [abstract no. A-49]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 16

  57. Perret C, Wessels DH. Oral bioavailability of the ketolide telithromycin (HMR 3647) is similar in both elderly and young subjects [abstract no. MoP250]. Clinical Microbiology and Infection 2000 May; 6 Suppl. 1: 203–4

    Google Scholar 

  58. Lenfant B, Perret C, Pascual M-H. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial, is unaffected by food [abstract no. P69]. J Antimicrob Chemother 1999; 44 Suppl. A: 55

    Google Scholar 

  59. Gehanno P, Passot V, Nabet P, et al. Telithromycin (HMR 3647) penetrates rapidly into tonsillar tissue achieving high and prolonged tonsillar concentrations. Clinical Microbiology and Infection 2000; 6 Suppl. 1: 204

    Google Scholar 

  60. Muller-Serieys C, Cantalloube C, Soler P, et al. HMR 3647 achieves high and sustained concentrations in broncho-pulmonary tissues [abstract no. P78]. J Antimicrob Chemother 1999; 44 Suppl. A: 57

    Google Scholar 

  61. Kadota J, Ishimatsu Y, Iwashita T, et al. The ketolide antimicrobial, telithromycin (HMR 3647) achieves high and sustained concentration in alveolar macrophages and bronchoalveolar epithelial lining fluid in healthy Japanese volunteers [abstract no. 2143]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto: 32

  62. Andrews J, Honeybourne D, Khair O, et al. Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses [abstract no. 658]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  63. Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology [abstract no. 2144]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  64. Sultan E, Namour F, Pascual MH, et al. Penetration of the ketolide, HMR 3647, in cantharidin-induced blister fluid [abstract no. A-47]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 15

  65. Pham Gia H, Roeder V, Namour F, et al. HMR 3647 achieves high and sustained concentrations in white blood cells in man [abstract no. P79]. J Antimicrob Chemother 1999; 44 Suppl. A: 57–8

    Google Scholar 

  66. Miossec-Bartoli C, Pilatre L, Peyron P, et al. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob Agents Chemother 1999 Oct; 43: 2457–62

    PubMed  CAS  Google Scholar 

  67. Sultan E, Namour F, Mauriac C, et al. HMR 3647, a new ketolide antimicrobial, is metabolised, and excreted mainly in faeces in man [abstract no. P63]. J Antimicrob Chemother 1999; 44 Suppl. A: 54

    Google Scholar 

  68. Aventis Pharma. Data on file. Ketek™ (telithromycin). Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. Aventis Pharma, Bridgewater, New Jersey, US; Executive summary, 2001 March

  69. Sultan E, Lenfant B, Wable C, et al. Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers [abstract no. P66]. J Antimicrob Chemother 1999; 44 Suppl. A: 54

    Google Scholar 

  70. Sultan E, Cantalloube C, Patat A, et al. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment [abstract no. MoP249]. Clinical Microbiology and Infection 2000; 6 Suppl. 1: 203

    Google Scholar 

  71. Pluim J. Population pharmacokinetics support the convenient once-daily 800 mg dosage of telithromycin in patients with upper and lower RTIs, including special populations [abstract no. P1263]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1–4; Istanbul. Clin Microbiol Infect 2001; 7 Suppl. 1: 266

    Google Scholar 

  72. Trémolières F, de Kock F, Pluck N, et al. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 447–53

    Article  PubMed  Google Scholar 

  73. O’Doherty B, Dutchman DA, Pettit R, et al. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 Suppl. A: 73–81

    Article  PubMed  Google Scholar 

  74. Genné D, Siegrist HH, Humair L, et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16(11): 783–8

    Article  PubMed  Google Scholar 

  75. Carbon C, Moola S, Velancsics I, et al. Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia [abstract no. 2245]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  76. Aventis Pharma. Data on file. Aventis Pharma study synopsis A/3009 Open-label. 2000 May

  77. Aventis Pharma. Data on file. Aventis Pharma study synopsis A/3010. 2001 Jan

  78. Hagberg L, Torres A, Van Rensburg DJ, et al. Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia [abstract no. 2244]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  79. Tellier G, Hassman J, Leroy B, et al. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults [abstract no. 2227]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  80. Leroy B, Rangaraju M. Efficacy of telithromycin (HMR 3647) in the treatment of bacteremia associated with community-acquired pneumonia [abstract no. 2223]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  81. Aventis Pharma. Data on file. Ketek™ (telithromycin). Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. Aventis Pharma, Bridgewater, New Jersey, US; Section 6.4.1 Community-acquired pneumonia, 2001 March: 90

  82. Leroy B, Rangaraju M. Efficacy of telithromycin (HMR 3647), a new once-daily ketolide, in community-acquired pneumonia caused by atypical pathogens [abstract no. 2225]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  83. Aventis Pharma. Data on file. Ketek™ (telithromycin). Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. Aventis Pharma, Bridgewater, New Jersey, US; Section 6.4.2 Acute exacerbations of chronic bronchitis, 2001 March: 94

  84. Aubier M, Aidons PM, Leak A, et al. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD [abstract no. 2241]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  85. Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis [abstract no. 2243]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  86. Quinn J, Ziter P, Leroy B, et al. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A-hemolytic streptococcal (GABHS) pharyngitis/tonsillitis [abstract no. 2229]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  87. Norrby SR, Rabie W, Bacart P, et al. Efficacy of 5 days’ telithromycin (HMR 3647) vs 10 days’ penicillin V in the treatment of pharyngitis in adults [abstract no. 2242]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  88. Rangaraju M, Leroy B. Clinical and bactriological efficacy of telithromycin (HMR 3647) in the treatment of community-acquired RTIs caused by S. pneumoniae with reduced susceptibility to penicillins or macrolides [abstract no. P1261]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1–4; Istanbul. Clin Microbiol Infect 2001; 7 Suppl. 1:265–6

    Google Scholar 

  89. Tellier G, Lasko B, Leroy B, et al. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid 500/125 mg three-times daily for 10 days in acute maxillary sinusitis (AMS) in adults [abstract no. 2226]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  90. Aventis Pharma. Data on file. Ketek™ (telithromycin). Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. Aventis Pharma, Bridgewater, New Jersy, US; Section 7.2.4.1 Diarrhea, 2001 March: 121–4

  91. Démolis JL, Cardus S, Vacheron F, et al. Effect of telithromycin on ventricular repolarization in healthy subjects [abstract no. 651]. 7th World Conference on Clinical Pharmacology and Therapeutics IUPHAR — Division of Clinical Pharmacology, and 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT); 2000 Jul 15–20; Florence, 168

  92. Labbe G, Flor M, Lenfant B. HMR 3647, a new ketolide antimicrobial, does not inhibit cytochrome P450 activity in vitro [abstract no. P95]. J Antimicrob Chemother 1999; 44 Suppl. A: 61

    Google Scholar 

  93. Aventis Pharma. Data on file. Ketek™ (telithromycin). Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. Aventis Pharma, Bridgewater, New Jersey, US; Section 5.5 Drug interactions, 2001 March: 59–62

  94. Lippert C, Leese PT, Sultan E. Telithromycin (HMR 3647) does not interact with the CYP2D6 substrate paroxetine [abstract no. P1268]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1–4; Istanbul. Clin Microbiol Infect 2001; 7 Suppl. 1: 267

    Google Scholar 

  95. Scholtz HE, Pretorius SG, Wessels DH, et al. HMR 3647, a new ketolide antimicrobia, does not affect the pharmacodynamics or pharmacokinetics of warfarin in healthy adult males [abstract no. 81]. Clin Infect Dis 1999 Oct; 29(4): 976

    Google Scholar 

  96. Scholtz HE, Sultan E, Wessels D, et al. HMR 3647, a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [abstract no. 10]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 3

  97. Lippert C, Leese PT, Sultan E. Effect of gastric pH on the bioavailability of telithromycin (HMR 3647) [abstract no. P1269]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1–4; Istanbul. Clin Microbiol Infect 2001; 7 Suppl. 1: 267

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Julia A. Barman Balfour & David P. Figgitt

Authors
  1. Julia A. Barman Balfour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Figgitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Figgitt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barman Balfour, J.A., Figgitt, D.P. Telithromycin. Drugs 61, 815–829 (2001). https://doi.org/10.2165/00003495-200161060-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161060-00016

Keywords

Search

Navigation